...
首页> 外文期刊>JMIR mHealth and uHealth >An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series
【24h】

An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series

机译:移动应用程序(OTOCALC)内的耳毒性分级系统,用于资源限制设定,以指导耐药结核病患者药物诱导的药物诱导的药物损失的评分和管理:前瞻性,横截面案例系列

获取原文
           

摘要

Background Tuberculosis (TB) affects millions of people worldwide and is treated with medication including aminoglycosides and polypeptides. Individuals respond differently to medications as a result of their genetic inheritance. These differences in genetic inheritance can result in the underdosing or overdosing of medication, which may affect the efficacy or, in the case of aminoglycosides and polypeptides used in the treatment of all forms of TB, result in ototoxicity. When ototoxicity is detected, physicians should adjust dosages to minimize further ototoxicity and hearing loss; however, there are no suitable grading systems to define significant hearing loss. Objective The aim of this study was to develop a standardized grading system by making use of an electronic health (eHealth) platform to ensure that a user-friendly method was available to interpret hearing test results, calculate significant hearing loss, and provide recommendations with regard to dosage adjustments and management. It further aimed to establish the sensitivity of the newly developed grading scale. Methods This grading system was developed in South Africa based on data that were obtained from an audiology and pharmacokinetic study on patients with drug-resistant TB (DR-TB) at two DR-TB units at state-run hospitals. This feasibility study employed a prospective, cross-sectional, exploratory, descriptive case series research design, with a total of 22 participants. Participants underwent audiological and pharmacological assessments at baseline and every 2 weeks for the first 3 months of treatment. Various professionals (8 in total) were subsequently involved in the development of the eHealth system, including a software engineer, four audiologists, a pharmacist, a medical doctor, and a nurse. The app underwent 14 modifications that involved aspects of data storage, ease of usability, grades, and the risk factor checklist. Results An ototoxicity grading system within a mobile app for use by doctors, nurses, and audiologists was developed for patients with DR-TB. The purpose of this user-friendly ototoxicity calculator, OtoCalc , is to (1) assist health professionals in assessing patients for ototoxicity, (2) establish the clinical significance of ototoxicity by calculating the grade of hearing loss, (3) monitor the progression of hearing loss, and (4) enable systematic referral and management of patients according to their needs. Conclusions This newly developed system is more sensitive than the existing grading methods for determining ototoxicity in patients with DR-TB. This app needs to be trialed in a larger sample to establish data security, ease of use, and suitability within this population.
机译:背景技术结核病(TB)影响全球数百万人,并用药物治疗,包括氨基糖苷和多肽。由于他们的遗传遗传,个人对药物的反应不同。这些遗传遗传的这些差异可能导致药物的推出或过量,这可能影响疗效或在治疗所有形式的TB中使用的氨基糖苷和多肽的情况下,导致耳毒性。当检测到耳毒性时,医生应调整剂量以最小化进一步的耳毒性和听力损失;然而,没有合适的分级系统来定义显着的听力损失。客观本研究的目的是通过利用电子健康(eHealth)平台来开发标准化的评分系统,以确保用户友好的方法可用于解释听力测试结果,计算大量听力损失,并提供关于方面的建议用法调整和管理。它进一步旨在建立新开发的分级规模的敏感性。方法采用该评分系统是在南非在南非的基础上开发,这些数据是从有耐药性TB(DR-TB)患者在国奔医院的两种DR-TB单位的患者中获得的数据。这种可行性研究采用了前瞻性横截面,探索性的描述性案例系列研究设计,共22名参与者。参与者在前3个月内接受基线和每2周的药物评估的药理学评估。随后参与了各种专业人士(总共8人)在eHealth系统的发展中,包括软件工程师,四名听力学家,药剂师,医生和护士。该应用程序介绍了14个修改,这些修改涉及数据存储,易用性,等级和风险因素核对表的方面。结果为DR-TB的患者开发了用于医生,护士和听力学家使用的移动应用程序中的ototoxicity分级系统。这种用户友好的otootoxicity计算器Otocalc的目的是(1)协助卫生专业人员评估耳毒性患者,(2)通过计算听力损失等级来确定耳毒性的临床意义,(3)监测进展听力损失,(4)根据其需求,可以实现对患者的系统推荐和管理。结论这一新开发的系统比现有的分级方法更敏感,用于确定DR-TB患者中耳毒性的分级方法。此应用程序需要在更大的样本中进行试验,以建立数据安全性,易用性和适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号